Developer docs
API playgroundTry for free, no card

Search company profiles

ArriVent

Full company profile

uuid00005ye

Namestring
ArriVent
Legal namestring
ArriVent BioPharma, Inc.
Websiteurl
arrivent.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

ArriVent BioPharma is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania, with collaboration sites in Gaithersburg, Maryland and Burlingame, California. The company trades on NASDAQ under the ticker AVBP. ArriVent identifies, in-licenses, and develops differentiated oncology medicines from partners in China, Europe, South Korea, and Japan, focusing on indications with high unmet medical need, particularly in EGFR-mutant non-small cell lung cancer (NSCLC). Its lead asset, firmonertinib, is an oral, highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical EGFR mutations as well as exon 20 insertion and PACC mutations; it is approved in China for classical EGFR-mutant NSCLC and is in global Phase 3 development (FURVENT and ALPACCA trials). The pipeline is expanding into antibody-drug conjugates through partnerships with Aarvik Therapeutics (ARR-002, a dual-target MUC16/NaPi2b ADC), Lepu Biopharma (ARR-217, a CDH17 ADC), and Alphamab Oncology (ARR-421 and ARR-173), alongside a clinical combination study with InnoCare's SHP2 inhibitor.

ArriVent's business model is the in-licensing and global clinical development of externally discovered oncology assets, with future revenue dependent on regulatory approval and commercialization of firmonertinib and subsequent pipeline candidates. The company is pre-revenue and currently funds operations through equity capital and debt; as of December 2025 it reported $312.8 million in cash supplemented by a $75 million undrawn credit facility, and in May 2026 completed a $250 million financing, extending runway into the second half of 2027. R&D expense was $153.4 million in FY2025, and the firm reported a $166.3 million net loss for the year.

Go-to-market preparation is underway: the company is building a commercial organization under Chief Commercial Officer Brent Rice, with Field Director Medical Affairs roles engaging oncologists and key opinion leaders at academic and community oncology centers. The company has secured FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib and FDA IND clearance for ARR-002, materially de-risking the regulatory pathway for its first two programs. The company was founded by Bing Yao (CEO, formerly CEO of Viela Bio) and Stuart Lutzker (President of R&D, formerly VP at Genentech), with senior leadership drawn largely from Viela Bio, MedImmune/AstraZeneca, Genentech, and Amgen.

Short descriptiontext

ArriVent BioPharma is a clinical-stage biopharmaceutical company that in-licenses and develops differentiated oncology therapies — led by the EGFR inhibitor firmonertinib and a pipeline of antibody-drug conjugates — for cancer patients with high unmet need, targeting global markets outside China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPennsylvania Furnace, United States
HQ citystring
Pennsylvania Furnace
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, targeted cancer therapies, EGFR inhibitors, antibody drug conjugates, clinical-stage biopharmaceutical
Industry5 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Anticipates generating revenue from commercialization of firmonertinib and other pipeline candidates upon regulatory approval.

arrivent.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ArriVent BioPharma is a clinical-stage biopharmaceutical company that identifies, in-licenses, develops, and plans to commercialize differentiated oncology medicines addressing unmet needs in difficult-to-treat cancers. Its lead candidate is firmonertinib, an oral, brain-penetrant EGFR inhibitor for NSCLC, supported by a pipeline of antibody-drug conjugates (ARR-002, ARR-217, ARR-421, ARR-173) targeting solid tumors in ovarian, endometrial, and gastrointestinal indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Firmonertinib approved in China for classical EGFR mutant NSCLC by Allist Pharmaceuticals
+4 more records
Product overview1 text field

ArriVent BioPharma is a clinical-stage biopharmaceutical company developing a pipeline of differentiated oncology therapeutics. The core product is firmonertinib, an oral EGFR inhibitor that has received FDA Breakthrough Therapy Designation for EGFR exon 20 insertion mutations and is in Phase 3 trials (FURVENT and ALPACCA). The pipeline includes multiple ADC candidates: ARR-002 (MUC16/NaPi2b dual-target, partnered with Aarvik Therapeutics), ARR-217 (CDH17 ADC from Lepu Biopharma), and ARR-421 and ARR-173 (from Alphamab Oncology partnership), targeting various solid tumors. The company operates through strategic partnerships to in-license promising drug candidates from global sources and advance them through development and potential commercialization.

Product and service5 records
1Firmonertinib (formerly Furmonertinib)
CategoryCore product (oncology small molecule)
Description

Oral, highly brain-penetrant, mutation-selective EGFR inhibitor active against both classical and uncommon EGFR mutations, including exon 20 insertion mutations and P-loop and aC-helix compressing (PACC) mutations, in development for non-small cell lung cancer (NSCLC). Approved in China for classical EGFR mutant NSCLC; FDA Breakthrough Therapy Designation granted for previously untreated EGFR exon 20 insertion NSCLC.

2ARR-002 (AV-P138-ADC)
CategoryPipeline product (oncology biologic / ADC)
Description

First-in-class dual-target MUC16/NaPi2b tetravalent antibody-drug conjugate (ADC) developed with Aarvik Therapeutics using the proprietary MUTTA and AQUALINK ADC platforms, with initial development focus on ovarian and endometrial cancers. Demonstrates superior anti-tumor activity compared to single-target ADCs and offers an improved therapeutic window.

3ARR-217
CategoryPipeline product (oncology biologic / ADC)
Description

CDH17-targeting antibody-drug conjugate (ADC) in-licensed from Lepu Biopharma with a potential best-in-class profile, in development for gastrointestinal (GI) cancers. ArriVent holds exclusive global rights outside Greater China.

4ARR-421
CategoryPipeline product (oncology biologic / ADC)
Description

Antibody-drug conjugate (ADC) candidate from the partnership with Alphamab Oncology, utilizing Alphamab's proprietary linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.

5ARR-173
CategoryPipeline product (oncology biologic / ADC)
Description

Antibody-drug conjugate (ADC) candidate from the partnership with Alphamab Oncology, utilizing Alphamab's proprietary linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Collaboration to advance ARR-002 (AV-P138-ADC), a novel dual-target MUC16/NaPi2b tetravalent ADC for ovarian and endometrial cancers. Aarvik is responsible for discovery and preclinical validation using MUTTA™ and AQUALINK™ platforms; ArriVent leads global development and commercialization.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensed firmonertinib from Allist for global development and commercialization outside China. Allist maintains China rights while ArriVent leads rest-of-world development. Firmonertinib is approved in China for classical EGFR mutant NSCLC under this partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for discovery, development, and commercialization of novel ADCs ARR-421 and ARR-173. Utilizes Alphamab's linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Exclusive license agreement for ARR-217, a potential best-in-class CDH17 ADC targeting gastrointestinal cancers. ArriVent obtained exclusive global rights outside Greater China for development and commercialization.

5Beijing InnoCare Pharma Tech Co., Ltd.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical combination study of furmonertinib with ICP-189 (SHP2 inhibitor) targeting advanced or metastatic NSCLC patients with EGFR classical mutations.

arrivent.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owns Tagrisso (osimertinib), the dominant EGFR TKI in EGFR-mutant NSCLC, and is expanding EGFR-directed combos (e.g., with amivantamab). The primary entrenched competitor shaping firmonertinib's commercial opportunity.

TypeDirect peer
Description

Clinical-stage oncology biotech advancing a pipeline that includes EGFR-directed therapies and ADCs targeting solid tumors. Direct overlap with ArriVent's lung cancer and ADC strategy.

TypeEmerging player
Description

Clinical-stage precision oncology biotech targeting the EGFR/RAS/MAPK pathway. Directly comparable mechanism-based approach to firmonertinib with similar stage and indication focus in NSCLC.

TypeBroad incumbent
Description

Global oncology-focused biopharmaceutical company with multiple targeted oncology and ADC programs. Comparable at the platform/business-model level as a global developer/commercializer of differentiated cancer therapies.

TypeBroad incumbent
Description

Pioneer in ADC drug development; its ovarian cancer ADC Elahere targets FRα, broadly comparable to ArriVent's ARR-002 in ovarian/endometrial cancers. Now part of AbbVie, giving it deeper commercial resources.

TypeBroad incumbent
Description

Roche/Genentech is a leading oncology franchise developer with established ADC and EGFR programs and is also where ArriVent's President R&D (Lutzker) led early oncology development. Highly relevant as a large-scale oncology incumbent and benchmarking reference.

TypeEmerging player
Description

Clinical-stage biotech developing next-generation ADCs across solid tumors. Comparable to ArriVent's pipeline ADCs in modality (ADCs), scale (clinical-stage, ~few hundred employees) and target patient populations.

TypeDirect peer
Description

Clinical-stage oncology biotech developing mutation-selective small molecules across EGFR and other oncogene targets in NSCLC. Like ArriVent, it focuses on differentiated, genetically defined patient subsets with limited treatment options.

TypeBroad incumbent
Description

Developed Krazati (adagrasib), an EGFR-pathway / KRAS G12C inhibitor for NSCLC, before being acquired by BMS. Highly comparable commercial-stage oncology small-molecule competitor in the same indication space as firmonertinib.

TypeRegional player
Description

Chinese partner that discovered firmonertinib and retains China rights where the drug is approved for classical EGFR mutant NSCLC. Operates in the same EGFR-mutant NSCLC space but solely in the Greater China market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ArriVent

Oncology Pharmaceuticalsarrivent.com

ArriVent BioPharma is a clinical-stage biopharmaceutical company that in-licenses and develops differentiated oncology therapies — led by the EGFR inhibitor firmonertinib and a pipeline of antibody-drug conjugates — for cancer patients with high unmet need, targeting global markets outside China.

What ArriVent does

ArriVent BioPharma is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania, with collaboration sites in Gaithersburg, Maryland and Burlingame, California. The company trades on NASDAQ under the ticker AVBP. ArriVent identifies, in-licenses, and develops differentiated oncology medicines from partners in China, Europe, South Korea, and Japan, focusing on indications with high unmet medical need, particularly in EGFR-mutant non-small cell lung cancer (NSCLC). Its lead asset, firmonertinib, is an oral, highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical EGFR mutations as well as exon 20 insertion and PACC mutations; it is approved in China for classical EGFR-mutant NSCLC and is in global Phase 3 development (FURVENT and ALPACCA trials). The pipeline is expanding into antibody-drug conjugates through partnerships with Aarvik Therapeutics (ARR-002, a dual-target MUC16/NaPi2b ADC), Lepu Biopharma (ARR-217, a CDH17 ADC), and Alphamab Oncology (ARR-421 and ARR-173), alongside a clinical combination study with InnoCare's SHP2 inhibitor.

ArriVent's business model is the in-licensing and global clinical development of externally discovered oncology assets, with future revenue dependent on regulatory approval and commercialization of firmonertinib and subsequent pipeline candidates. The company is pre-revenue and currently funds operations through equity capital and debt; as of December 2025 it reported $312.8 million in cash supplemented by a $75 million undrawn credit facility, and in May 2026 completed a $250 million financing, extending runway into the second half of 2027. R&D expense was $153.4 million in FY2025, and the firm reported a $166.3 million net loss for the year.

Go-to-market preparation is underway: the company is building a commercial organization under Chief Commercial Officer Brent Rice, with Field Director Medical Affairs roles engaging oncologists and key opinion leaders at academic and community oncology centers. The company has secured FDA Breakthrough Therapy Designation and Orphan Drug Designation for firmonertinib and FDA IND clearance for ARR-002, materially de-risking the regulatory pathway for its first two programs. The company was founded by Bing Yao (CEO, formerly CEO of Viela Bio) and Stuart Lutzker (President of R&D, formerly VP at Genentech), with senior leadership drawn largely from Viela Bio, MedImmune/AstraZeneca, Genentech, and Amgen.

ArriVent firmographics

Firmographics
Name
ArriVent
Legal name
ArriVent BioPharma, Inc.
Website
https://arrivent.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
ArriVent BioPharma is a clinical-stage biopharmaceutical company that in-licenses and develops differentiated oncology therapies — led by the EGFR inhibitor firmonertinib and a pipeline of antibody-drug conjugates — for cancer patients with high unmet need, targeting global markets outside China.
Ownership category
akta.pro rank

ArriVent industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Oncology drug development
  • Targeted cancer therapies
  • EGFR inhibitors
  • Antibody drug conjugates
  • Clinical-stage biopharmaceutical

Where ArriVent is headquartered

Location

Headquarters

HQ city
Pennsylvania Furnace
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ArriVent business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Pre-revenue clinical-stage company. Anticipates generating revenue from commercialization of firmonertinib and other pipeline candidates upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

ArriVent product offering

Product offering

Core offering

ArriVent BioPharma is a clinical-stage biopharmaceutical company that identifies, in-licenses, develops, and plans to commercialize differentiated oncology medicines addressing unmet needs in difficult-to-treat cancers. Its lead candidate is firmonertinib, an oral, brain-penetrant EGFR inhibitor for NSCLC, supported by a pipeline of antibody-drug conjugates (ARR-002, ARR-217, ARR-421, ARR-173) targeting solid tumors in ovarian, endometrial, and gastrointestinal indications.

Product overview

ArriVent BioPharma is a clinical-stage biopharmaceutical company developing a pipeline of differentiated oncology therapeutics. The core product is firmonertinib, an oral EGFR inhibitor that has received FDA Breakthrough Therapy Designation for EGFR exon 20 insertion mutations and is in Phase 3 trials (FURVENT and ALPACCA). The pipeline includes multiple ADC candidates: ARR-002 (MUC16/NaPi2b dual-target, partnered with Aarvik Therapeutics), ARR-217 (CDH17 ADC from Lepu Biopharma), and ARR-421 and ARR-173 (from Alphamab Oncology partnership), targeting various solid tumors. The company operates through strategic partnerships to in-license promising drug candidates from global sources and advance them through development and potential commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

  • Firmonertinib (formerly Furmonertinib) Oral, highly brain-penetrant, mutation-selective EGFR inhibitor active against both classical and uncommon EGFR mutations, including exon 20 insertion mutations and P-loop and aC-helix compressing (PACC) mutations, in development for non-small cell lung cancer (NSCLC). Approved in China for classical EGFR mutant NSCLC; FDA Breakthrough Therapy Designation granted for previously untreated EGFR exon 20 insertion NSCLC.
  • ARR-002 (AV-P138-ADC) First-in-class dual-target MUC16/NaPi2b tetravalent antibody-drug conjugate (ADC) developed with Aarvik Therapeutics using the proprietary MUTTA and AQUALINK ADC platforms, with initial development focus on ovarian and endometrial cancers. Demonstrates superior anti-tumor activity compared to single-target ADCs and offers an improved therapeutic window.
  • ARR-217 CDH17-targeting antibody-drug conjugate (ADC) in-licensed from Lepu Biopharma with a potential best-in-class profile, in development for gastrointestinal (GI) cancers. ArriVent holds exclusive global rights outside Greater China.
  • ARR-421 Antibody-drug conjugate (ADC) candidate from the partnership with Alphamab Oncology, utilizing Alphamab's proprietary linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.
  • ARR-173 Antibody-drug conjugate (ADC) candidate from the partnership with Alphamab Oncology, utilizing Alphamab's proprietary linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.

Quantifiable outcome

  • Firmonertinib approved in China for classical EGFR mutant NSCLC by Allist Pharmaceuticals
  • +4 more outcomes

Companies that use ArriVent

Customer profile

Segments3 records

Ideal customer profiles4 records

ArriVent technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ArriVent partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Aarvik TherapeuticscoreStrategic or Co-development Partner · 17 March 2026Collaboration to advance ARR-002 (AV-P138-ADC), a novel dual-target MUC16/NaPi2b tetravalent ADC for ovarian and endometrial cancers. Aarvik is responsible for discovery and preclinical validation using MUTTA™ and AQUALINK™ platforms; ArriVent leads global development and commercialization.
  • Shanghai Allist PharmaceuticalscoreStrategic or Co-development PartnerLicensed firmonertinib from Allist for global development and commercialization outside China. Allist maintains China rights while ArriVent leads rest-of-world development. Firmonertinib is approved in China for classical EGFR mutant NSCLC under this partnership.
  • Alphamab OncologyminorStrategic or Co-development PartnerPartnership for discovery, development, and commercialization of novel ADCs ARR-421 and ARR-173. Utilizes Alphamab's linker-payload platform and glycan-conjugation technology. ArriVent holds exclusive worldwide rights outside Greater China.
  • Lepu BiopharmaminorStrategic or Co-development PartnerExclusive license agreement for ARR-217, a potential best-in-class CDH17 ADC targeting gastrointestinal cancers. ArriVent obtained exclusive global rights outside Greater China for development and commercialization.
  • Beijing InnoCare Pharma Tech Co., Ltd.minorStrategic or Co-development PartnerClinical combination study of furmonertinib with ICP-189 (SHP2 inhibitor) targeting advanced or metastatic NSCLC patients with EGFR classical mutations.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

ArriVent competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Owns Tagrisso (osimertinib), the dominant EGFR TKI in EGFR-mutant NSCLC, and is expanding EGFR-directed combos (e.g., with amivantamab). The primary entrenched competitor shaping firmonertinib's commercial opportunity.
  • Takeda Pharmaceutical: Global oncology-focused biopharmaceutical company with multiple targeted oncology and ADC programs. Comparable at the platform/business-model level as a global developer/commercializer of differentiated cancer therapies.
  • ImmunoGen (AbbVie): Pioneer in ADC drug development; its ovarian cancer ADC Elahere targets FRα, broadly comparable to ArriVent's ARR-002 in ovarian/endometrial cancers. Now part of AbbVie, giving it deeper commercial resources.
  • Genentech (Roche): Roche/Genentech is a leading oncology franchise developer with established ADC and EGFR programs and is also where ArriVent's President R&D (Lutzker) led early oncology development. Highly relevant as a large-scale oncology incumbent and benchmarking reference.
  • Mirati Therapeutics (Bristol-Myers Squibb): Developed Krazati (adagrasib), an EGFR-pathway / KRAS G12C inhibitor for NSCLC, before being acquired by BMS. Highly comparable commercial-stage oncology small-molecule competitor in the same indication space as firmonertinib.

Direct peers

  • Cullinan Oncology: Clinical-stage oncology biotech advancing a pipeline that includes EGFR-directed therapies and ADCs targeting solid tumors. Direct overlap with ArriVent's lung cancer and ADC strategy.
  • Black Diamond Therapeutics: Clinical-stage oncology biotech developing mutation-selective small molecules across EGFR and other oncogene targets in NSCLC. Like ArriVent, it focuses on differentiated, genetically defined patient subsets with limited treatment options.

Emerging players

  • Erasca: Clinical-stage precision oncology biotech targeting the EGFR/RAS/MAPK pathway. Directly comparable mechanism-based approach to firmonertinib with similar stage and indication focus in NSCLC.
  • Mersana Therapeutics: Clinical-stage biotech developing next-generation ADCs across solid tumors. Comparable to ArriVent's pipeline ADCs in modality (ADCs), scale (clinical-stage, ~few hundred employees) and target patient populations.

Regional players

  • Allist Pharmaceuticals: Chinese partner that discovered firmonertinib and retains China rights where the drug is approved for classical EGFR mutant NSCLC. Operates in the same EGFR-mutant NSCLC space but solely in the Greater China market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ArriVent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ArriVent leadership team

Management profile

Number of profiles

Profiles12 records

ArriVent funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ArriVent M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ArriVent

What does ArriVent do?

ArriVent BioPharma is a clinical-stage biopharmaceutical company that identifies, in-licenses, develops, and plans to commercialize differentiated oncology medicines addressing unmet needs in difficult-to-treat cancers. Its lead candidate is firmonertinib, an oral, brain-penetrant EGFR inhibitor for NSCLC, supported by a pipeline of antibody-drug conjugates (ARR-002, ARR-217, ARR-421, ARR-173) targeting solid tumors in ovarian, endometrial, and gastrointestinal indications.

Is ArriVent a public or private company?

ArriVent is a public company. It is classified as public and is currently operating.

When was ArriVent founded?

ArriVent was founded in 2021. It employs 51 to 100 people.

Where is ArriVent based?

ArriVent is headquartered in Pennsylvania Furnace, United States, in the North America region.

How does ArriVent make money?

One revenue line is on record: pharmaceutical product sales.

Who are ArriVent's main competitors?

Broad incumbents on record are AstraZeneca, Takeda Pharmaceutical, ImmunoGen (AbbVie), Genentech (Roche) and Mirati Therapeutics (Bristol-Myers Squibb). Direct peers are Cullinan Oncology and Black Diamond Therapeutics. Emerging players are Erasca and Mersana Therapeutics. Allist Pharmaceuticals is listed as a regional player.

Does ArriVent have an API?

No public API is recorded for ArriVent.

What industry is ArriVent in?

ArriVent's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comGuggenheim lowers ArriVent BioPharma stock price target to $28Guggenheim lowered its price target on ArriVent BioPharma to $28 from $30, keeping a Buy rating. The company's Q3 2026 results showed a Phase 3 miss for FURVENT in NSCLC, and the stock is down 53% over six months. ArriVent plans a firmonertinib update in Q1 2027.Seeking AlphaArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell (Rating Upgrade)ArriVent BioPharma's ARR-217 showed a 44.8% response rate in early colorectal cancer data, though only seven responses were confirmed. The company's firmonertinib Phase 3 failed, and shares fell another 14% after a Strong Sell downgrade. The analyst upgraded to Hold, citing pipeline potential and $393 million in cash.American Banking and Market NewsArriVent BioPharma (NASDAQ:AVBP) Upgraded to Hold at Wall Street ZenWall Street Zen upgraded ArriVent BioPharma from Sell to Hold. The stock has a consensus rating of Moderate Buy with an average price target of $24.89. The company reported Q3 EPS of -$0.81, beating estimates of -$1.05.American Banking and Market NewsArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on MondayArriVent BioPharma is expected to announce Q3 2026 earnings on November 16, with analysts projecting a loss of $1.04 per share and revenue of $0.80 million. The company's average analyst price target is $24.56, with an average rating of Moderate Buy.AktienArrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP InvestmentsKirby McInerney LLP continues investigating Arrivent Biopharma for possible securities law violations after its Phase 3 FURVENT trial failed to meet its primary endpoint. The stock fell 47.3% to $15.01 on October 6, 2026, and no lawsuit has been filed yet.Investing.comTruist raises ArriVent BioPharma stock price target on drug dataTruist raised its price target on ArriVent BioPharma to $21 from $18, citing a 44.8% preliminary objective response rate for ARR-217 in metastatic colorectal cancer. The firm expects first-half 2027 Phase 1b data to provide more mature progression-free survival data. Other analysts also adjusted targets, with H.C. Wainwright raising to $47.TradingViewGuggenheim maintains Buy rating on ArriVent BioPharma, $30 price targetGuggenheim maintained a Buy rating on ArriVent BioPharma with a $30 price target, implying 95.3% upside from the Oct 26 close. The firm raised ARR-217's probability of success to 45% from 20% and cited a 38% objective response rate at 6 mg/kg.TradingViewArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% UpsideAnalysts' average price target for ArriVent BioPharma rose to $24 from $22.91, implying about 14% upside from the Oct. 23 close. The consensus remains a Buy across 12 analysts, with forecasts ranging from $15 to $30 per share.The future of tradingArriVent Biopharma Presents Initial Phase 1 Data for ARR-217 in Advanced Solid TumorsArriVent Biopharma presented initial Phase 1 data for ARR-217 in 123 patients, including 113 with colorectal cancer. Grade 3 or higher treatment-related adverse events affected 30.1% of patients, and serious events occurred in 19.5%. The maximum tolerated dose was not reached, with dose-limiting toxicity at 8 mg/kg.MarketWatchArriVent BioPharma Shares Gain on Study Data for Gastrointestinal Cancer TreatmentArriVent BioPharma shares rose 9.3% after announcing positive Phase 1 data for its gastrointestinal cancer treatment ARR-217. The drug showed a 45% objective response rate at 6 mg in pretreated colorectal cancer patients, with a 93% disease control rate. The company advanced ARR-217 to Phase 1b dose optimization and expects further data in 2027.